Differential Diagnosis – Hepatitis

Contact Hours: 2

Author(s):

R.E. Hengsterman RN, BS, MA MSN, M.E. 

Course Overview

This course explores Hepatitis, emphasizing viral and non-viral etiologies, including hepatotropic viruses (hepatitis A, B, C, D, E), drug-induced liver injury, autoimmune Hepatitis, alcoholic liver disease, ischemic Hepatitis, and metabolic disorders. Participants will gain insight into the epidemiology, pathophysiology, clinical manifestations, diagnostic strategies, and differential diagnosis of acute and chronic Hepatitis, with attention to differentiating between various etiologies through clinical assessment and serologic testing. The course examines treatment protocols, targeted antiviral therapies, immunosuppressive treatments for autoimmune Hepatitis, and preventive strategies such as vaccination, patient education, and harm reduction measures.  

Course Outline

  1. Introduction 
  2. Etiology of Viral Hepatitis  
  3. Epidemiology of Viral Hepatitis  
  4. Etiology of Non-Viral Hepatitis  
  5. Epidemiology of Non-Viral Hepatitis
  6.  Alcoholic Hepatitis
  7. Autoimmune Hepatitis (AIH)
  8. Ischemic Hepatitis (Shock Liver)
  9. Metabolic and Genetic Liver Diseases
  10. Nonalcoholic Fatty Liver Disease (NAFLD) & Nonalcoholic Steatohepatitis (NASH)
  11. Differential Diagnosis of Viral Hepatitis
  12. History & Physical  
  13. Differential Diagnosis Case Study: Chronic Hepatitis  
  14. Treatment of Viral Hepatitis  
  15. Deterrence and Patient Education 
  16. Conclusion 

Course Outcomes

After completing this course, the learner will rate a 4 out of 5 on the Likert Scale for their ability to:

  1. Identify key differences between acute and chronic Hepatitis, including clinical manifestations, phases of disease progression, and potential complications such as cirrhosis and hepatocellular carcinoma. 
  2. Distinguish between viral Hepatitis (HAV, HBV, HCV, HDV, HEV) and non-viral Hepatitis (autoimmune, drug-induced liver injury, alcoholic Hepatitis, ischemic Hepatitis, metabolic/genetic conditions), highlighting key diagnostic indicators, transmission routes, and clinical relevance. 
  3. Identify the diagnostic approaches, including serological tests, liver function tests, and imaging modalities, and differentiate hepatitis etiologies. 
  4. Recognize the global and regional epidemiology of Hepatitis, including prevalence, transmission patterns, high-risk populations, and the impact on public health initiatives, prevention strategies, and healthcare resources. 
  5. Recognize the appropriate treatment plans for distinct hepatitis types, incorporating current antiviral therapies, immunosuppressive treatments, supportive care, and patient education strategies focused on prevention, lifestyle modifications, and risk reduction. 

Accreditations and Approvals

CE Credit Logo
  • American Nurses Credentialing Center (ANCC) (P0614)
  • California Board of Registered Nursing (CEP 17418)
  • Kentucky Board of Nursing (7-0090)
  • Louisiana State Board of Nursing (58)
  • Florida Board of Nursing (50-23983)
  • Delaware Board of Nursing (DE-24-010127)
  • Alabama Board of Nursing (#ABNP1577)
  • Iowa Board of Nursing (#393)
  • Kansas Board of Nursing (LT0340-0325)

Approved by the Board of Nursing in every state, you can complete your RN, LVN, and APRN CEUs with confidence.

Accreditation Statement

Nursing CE Central LLC is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

It will take the average learner 120 minutes to complete and awards 2 contact hours of continuing education.

Written For

  • Advanced Practice Registered Nurses (APRN)

Requirements for Completion

  1. Enrollment in the course by the learner
  2. Read and learn all course materials
  3. Complete the course evaluation
  4. Attest and testify learning of the course materials

Disclosure of Relevant Financial Relationships

Nursing CE Central nor any of the authors, planners, content experts, or any contributors have any relevant financial relationships with ineligible companies to disclose.